Evaluating the Effects of Acarbose on Anthropometry Indexes and Metabolic Markers in Patients with Metabolic Syndrome in Comparison to Placebo, in Isfahan City, Iran

Document Type : Original Article (s)

Authors

1 Assistant Professor, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Resident, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Metabolic syndrome (MTS) is a group of metabolic abnormalities that occur simultaneously. Acarbose is an anti-diabetes medication that studies showed its effects on improving lipid profile, blood sugar, insulin resistance, and weight loss. This study aimed to evaluate the effects of acarbose on anthropometry indexes and metabolic markers in patients with metabolic syndrome in comparison to placebo, in Isfahan City, Iran.Methods: This was a randomized clinical trial study on patients with metabolic syndrome who referred to Sedighe Tahere Research Institute. Patients were randomly divided into two groups treated with acarbose or placebo for 6 months. Before and after intervention, weight, waist circumference, and hip circumference were measured, and the level of fasting blood sugar, postprandial blood sugar (30 minutes, and 1 and 2 hours), cholesterol, triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), liver enzymes, albumin, C-reactive protein (CRP), insulin (fast, and 30 minutes, and 1 and 2 hours postprandial), and insulin resistance index (Homeostatic Model Assessment of Insulin Resistance or HOMA-IR) were evaluated and then compared.Findings: In this study, 74 patients with metabolic syndrome with mean age of 39.9 ± 8.5 years were evaluated, of them, 27.02% were men. The mean weight (P < 0.001), waist circumference (P < 0.001), hip circumference (P < 0.001), and 1-hour (P < 0.010) and 2-hour postprandial blood sugar (P < 0.001) decreased significantly in acarbose group, the mean level of HDL significantly increased (P = 0.020), and HOMA-IR significantly decreased (P = 0.020). Other variables did not show significant differences.Conclusion: Acarbose can reduce weight and abdominal obesity, and improve postprandial blood sugar level, HDL level, and insulin resistance status.

Keywords

References

  1. Fakhrzadeh H, Ebrahimpour P, Pourebrahim R, Heshmat R, Larijani B. Metabolic syndrome and its associated risk factors in healthy adults: apopulation-based study in Iran. Metab Syndr Relat Disord 2006; 4(1): 28-34.
  2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735-52.
  3. Nakhaee A, Sanjari M. Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman. J Res Med Sci 2013; 18(5): 391-4.
  4. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 2015; 313(19): 1973-4.
  5. Azizi F, Hadaegh F, Khalili D, Esteghamati A, Hosseinpanah F, Delavari A, et al. Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity. Arch Iran Med 2010; 13(5): 426-8.
  6. Lin BJ, Wu HP, Huang HS, Juang JH, Sison A, bin Abdul Kadir DK, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003; 17(4): 179-85.
  7. Siraj ES. Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes? Cleve Clin J Med 2003; 70(8): 702-4.
  8. DiNicolantonio JJ, Bhutani J, O'Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart 2015; 2(1): e000327.
  9. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997; 103(6): 483-90.
  10. Joshi SR, Standl E, Tong N, Shah P, Kalra S, Rathod R. Therapeutic potential of alpha-glucosidase inhibitors in type 2 diabetes mellitus: An evidence-based review. Expert Opin Pharmacother 2015; 16(13): 1959-81.
  11. Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab 2015; 19(1): 160-4.
  12. Laube H. [Acarbose, a reliable therapeutic principle]. Med Klin (Munich ) 2003; 98(Suppl 1): 2-6.
  13. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65(3): 385-411.
  14. Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Fogari E, et al. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. Clin Drug Investig 2006; 26(9): 529-39.
  15. Zhang JP, Wang N, Xing XY, Yang ZJ, Wang X, Yang WY. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels. J Diabetes 2016; 8(4): 559-67.
  16. Homma Y, Irie N, Yano Y, Nakaya N, Goto Y. Changes in plasma lipoprotein levels during medication with a glucoside-hydrolase inhibitor (acarbose). Tokai J Exp Clin Med 1982; 7(3): 393-6.
  17. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: Results of a 25-year follow-up study. Lancet 1992; 340(8825): 925-9.
  18. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54(11): 3252-7.
  19. Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin 2009; 25(3): 607-15.
  20. Derosa G, Maffioli P, Ferrari I, Fogari E, D'Angelo A, Palumbo I, et al. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol 2011; 651(1-3): 240-50.
  21. Bayraktar F, Hamulu F, Ozgen AG, Yilmaz C, Tuzun M, Kabalak T. Acarbose treatment in obesity: A controlled study. Eat Weight Disord 1998; 3(1): 46-9.
  22. Hauner H, Petzinna D, Sommerauer B, Toplak H. Effect of acarbose on weight maintenance after dietary weight loss in obese subjects. Diabetes Obes Metab 2001; 3(6): 423-7.
Journal of Isfahan Medical School
Volume 36, Issue 485 - Serial Number 485
May and June 2018
Pages 723-730

Files

History

  • Receive Date: 16 May 2018
  • Revise Date: 23 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics